Summaries of our Zeolite-Studies
Methodology Of The Study
PANACEO has been pioneering the systematic research of PMA zeolite for human use since the turn of the millennium.
The first step, as a prerequisite for further studies, was the safety of the active ingredient for oral administration - demonstrated with studies according to both OECD drug standards and EN ISO standards.
Thus, the necessary prerequisite for numerous application studies under medical supervision had already been met from the beginning of 2000.
Very early on, pre-clinical studies as well as clinical observations showed an outstanding positive effectiveness on oxidative stress, a significant lactate reduction during physical exertion and the improvement of well-being in accompanying use with drug therapies. In addition, already in this early phase of application, an outstanding effectiveness on different intestinal disorders was shown. These effects were accompanied by selective binding and elimination of very specific toxins and ammonium in the gastrointestinal tract.
All these findings and study results were documented accordingly and finally led to the first certification as a medical product in 2006.
Since then, many of the effects experienced in practice - first through use in the clinical field - have been repeatedly investigated in greater depth in standardized, independent studies, again with our own products or our own active ingredient (PMA zeolite), and proven in accordance with the evidence-based scientific approach according to the gold standard.
Our Research Focus
Our research focus is intestinal health, in particular the protective function of the intestinal wall.
If the intestinal wall loses its natural protective and filtering function, this is called "leaky gut". As a result, more undesirable substances (e.g. bacterial components) can enter the body from the intestine, which not only burden the intestine itself (local inflammatory reactions) but also the immune system and downstream organs (systemic inflammatory reactions).
In this context one speaks of a so-called endotoxemia. Because the effects on the organs can originate in the intestine, science is increasingly concerned with the so-called intestine-body axes.
In the course of its research activities, PANACEO is also concerned with the effect of PMA zeolite on the intestine or the integrity of the intestinal wall (leaky gut) and its effects on our organism and the associated diseases.
PANACEO's research results confirm the natural support of intestinal health in the following areas:
- For leaky gut and associated factors such as irritable bowel syndrome or elevated liver enzymes,
- For better tolerability of medication therapies
- To support bone metabolism (osteoporosis)
- Pollutant prevention
- To support physical performance/strength through a strong intestine
Studies At A Glance
RCT - Leaky Gut
Study Design:
randomized, double-blind, placebo-controlled
Inclusion Criteria:
Adults who suffered from severe physical stress and had minimal increased permeability (zonulin above cut off).
Duration:
12 Weeks
Number of Patients:
52
Dosage:
2 x daily orally 2 g PMA zeolite or micro-crystalline cellulose (control)
Diagnostics:
Symptom load, blood & stool inflammation parameters such as alpha-1-antitrypsin, C-reactive protein, IL-10 and changes in the gut microbiome.
Study Director:
Doz. Mag. DDr. Manfred Lamprecht, Green Beat Institut
Scientific Journal:
Journal of the International Society of Sports Nutrition
Zonuline-concentration within the stool in the verum or placebo group after 0 and
12 weeks of supplementation. Values are medians ± SD, p < 0.05 (ANOVA), n = 27 (verum),
n = 25 (placebo).
Results:
- Significant improvement of intestinal wall functionality (zonulin p < 0.05)
- Evidence of anti-inflammatory tendency (IL 10 p < 0.1).
RCT - Irritable Bowel Syndrome - Pilot Study
Study Design:
randomized, double-blind, placebo-controlled
Inclusion Criteria:
Patients with irritable bowel syndrome, flatulence, diarrhea or constipation.
Duration:
2 Months
Number of Patients:
41
Dosage:
2 x daily orally 3 g PMA zeolite or micro-crystalline cellulose (control)
Diagnostics:
Symptom load, blood & stool inflammation parameters such as alpha-1-antitrybsin, C-reactive protein, IL-10 and changes in the gut microbiome.
Study Director:
Prof. med. V. Petkov
Scientific Journal:
Neuroendoctrinology Letters - international peer-reviewed interdisciplinary medical journal.
a-1 antitrypsin in stool (mg/dl) at the beginning of the pilot study (= baseline) and after 12 weeks. The mean value is statistically significantly reduced in the verum group compared to the placebo group (p = 0.037).
Results:
- significant decrease in the inflammatory parameter alpha-1-antitrypsin (p < 0.037)
- decrease of aluminum load in whole blood (p < 0.056)
- Increase in bifidobacteria and Lactobacillius species
NIS - MED GUT-REPAIR Lowers Liver Values
Study Design:
NIS (non-interventional study)
Inclusion Criteria:
Elevated Liver Enzymes
Duration:
2 Months
Number of Patients:
130 Austria-wide
Dosage:
2 x daily orally 3 g PMA zeolite
Diagnostics:
Blood Count: GGT, GOT und GPT
Study Director:
Dr. Tanja Oberwinkler
Scientific Journal:
Study not published
Results:
- A significant decrease in liver enzymes was detected in 2/3 of the patients, indicating the strengthening of the intestinal-liver axis.
RCT - Better Tolerability of Chemotherapies
Study Design:
randomized, double-blind, placebo-controlled
Inclusion Criteria:
Histologically confirmed cancer diagnosis, ≥ 18 years, predominantly colorectal carcinoma.
Duration:
3.5 Years (April 2015 to Oktober 2018)
Intake 7 Months
Number of Patients:
120
Dosage:
2 x daily orally 3 g of PMA zeolite during and up to 1 month after completion of chemotherapy (taking into account the time interval with other medications and suspending for two days before and after therapy) for 7 months.
Diagnostics:
CIPN (chemotherapy-induced polyneuropathy), hematologic toxicity, hepatoxicity during chemotherapy cycle.
Chemotherapeutic agents: FolFox, Xelox - adjuvant, first or second line
Measurement of nerve conduction velocity before initiation and at each of 3 and 6 months.
Study Director:
Prof. G. Carteni, Dr. med. M. G. Vitale
Department of Medical Oncology, Neapel, (A. Cardarelli)
Scientific Journal:
Molecules, Open Access Journal by MDPI
Results:
- Men and women had significantly fewer treatment discontinuations
(p < 0.03) - Men and women had better blood counts (p < 0.09)
- Men had significantly fewer chemotherapy-induced peripheral neuropathies (tingling or numbness in the limbs p < 0.047)
RCT - Osteoporosis
Study Design:
randomized, double-blind, placebo-controlled
Inclusion Criteria:
BMD-T score ≤ -2.5. Participants were untreated or had discontinued treatment. Exclusion for severe diseases such as cancer, autoimmune diseases, chronic renal failure and secondary osteoporosis, and pregnant women. All female participants had postmenopausal osteoporosis.
Duration:
12 Months
Number of Patients:
100
Dosage:
3 x daily 3 g each of PMA zeolite
Diagnostics:
BMD (qunatified bone density, essential for diagnosis).
Osteocalcin level (bone formation) Beta-crosslaps (bone resorption)
Pain: VAS - Visual Analog Scale
Subjective assessment of health quality
Study Director:
Prof. Dr. Sc. Dalibor Krpan, K-Centar in Zagreb
Scientific Journal:
Experimental Biology and Medicine (EBM)
Results:
81 of 100 patients completed the study.
PMA zeolite group vs. placebo shows:
- an increase in bone mineral density (BMD)
- increased level markers indicative of bone bonding (osteocalcin, beta-crosslaps)
- significant reduction in pain - visual analog scale (VAS)
- significantly improved quality of life compared to placebo.
Conclusions:
PMA zeolite ➡ innovative approach to osteoporosis.
- promotes bone bonding and
- decreased bone resorption
